RESUMEN
OBJECTIVE: This study investigates auditory processing in infants with West syndrome (WS) using event-related potentials (ERPs). METHODS: ERPs were measured in 25 infants with mainly symptomatic WS (age range = 3-10 months) and 26 healthy term infants (age range = 3-9 months) using an auditory novelty oddball paradigm. The ERP recordings were made during wakefulness and repeated in stage II sleep. RESULTS: The obligatory components (P150, N250, P350) and novelty response components (P300, Nc) were recordable during both sleep and wakefulness in patients and controls. All ERP latencies decreased with age in controls but not in the WS group (age × group interaction, F = 22.3, p < 0.0001). These ERP latency alterations were not affected by pharmacological treatment for WS. INTERPRETATION: This study demonstrated a persistently altered ERP signature in patients with a recent history of infantile spasms. The prolongation of auditory obligatory and novelty ERPs in WS patients indicates a severe failure of temporal lobe maturation during infancy. It remains to be investigated whether this predicts long-term cognitive impairments characteristic for this epileptic encephalopathy.
Asunto(s)
Potenciales Evocados Auditivos/fisiología , Espasmos Infantiles/patología , Lóbulo Temporal/fisiopatología , Estimulación Acústica , Estudios de Casos y Controles , Variación Contingente Negativa/efectos de los fármacos , Electroencefalografía , Potenciales Evocados Auditivos/efectos de los fármacos , Femenino , Humanos , Lactante , Estudios Longitudinales , Imagen por Resonancia Magnética , Masculino , Estudios Prospectivos , Tiempo de Reacción/efectos de los fármacos , Espasmos Infantiles/tratamiento farmacológico , Espasmos Infantiles/fisiopatologíaRESUMEN
The efficacy of tyrosine, a catecholamine precursor, as a countermeasure in the reduction of cognitive decline during heat exposure (HE) using event-related potential P300, and contingent negative variation (CNV) was evaluated. Ten healthy males, age 20-30years participated in the study. Volunteers received placebo or tyrosine (6.5g) 90min prior to HE (1.5h in 45°C+30% RH). P300 latency was significantly increased (p<0.01) during exposure with placebo, which was reduced significantly (p<0.01) after tyrosine supplementation. There was an increase in CNV M100 latency (p<0.05) and reaction time (p<0.01) and decrease in M100 amplitude (p<0.01) during HE with placebo, which returns to near normal level with the tyrosine administration. A significantly higher plasma norepinephrine (p<0.05), dopamine and epinephrine levels were detected in tyrosine supplemented group post heat exposure. HE increases the brain catecholamine activity thereby reduces the plasma norepinephrine and dopamine level leading to a reduction in cognitive performances. Tyrosine supplementation increases the catecholamine level and reduces the impairment of cognitive performance during HE.
Asunto(s)
Encéfalo , Catecolaminas/metabolismo , Variación Contingente Negativa/fisiología , Potenciales Relacionados con Evento P300/fisiología , Calor/efectos adversos , Desempeño Psicomotor/fisiología , Tirosina/farmacología , Adulto , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/fisiopatología , Variación Contingente Negativa/efectos de los fármacos , Dopamina/sangre , Electroencefalografía , Epinefrina/sangre , Potenciales Relacionados con Evento P300/efectos de los fármacos , Humanos , Masculino , Norepinefrina/sangre , Placebos , Desempeño Psicomotor/efectos de los fármacos , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Resultado del Tratamiento , Tirosina/administración & dosificación , Adulto JovenRESUMEN
OBJECTIVES: Bipolar disorder and schizophrenia share common pathophysiological processes and may have similar perceptual abnormalities. Mismatch negativity (MMN) and P3a - event-related potentials associated with auditory preattentional processing - have been extensively studied in schizophrenia, but rarely in bipolar disorder. Furthermore, MMN and P3a have not been examined between diagnostic subgroups of patients with bipolar disorder. We evaluated MMN and P3a in patients with bipolar disorder compared to patients with schizophrenia and healthy controls. METHODS: MMN and P3a were assessed in 52 bipolar disorder patients, 30 schizophrenia patients, and 27 healthy control subjects during a duration-deviant auditory oddball paradigm. RESULTS: Significant MMN and P3a amplitude reductions were present in patients with bipolar disorder and schizophrenia relative to controls. The MMN reduction was more prominent in patients with schizophrenia than bipolar disorder, at a trend level. P3a did not differ significantly between patient groups. There were no MMN or P3a differences between patients with bipolar I (n = 34) and bipolar II (n = 18) disorder. Patients with bipolar I disorder failed to show lateralized MMN, in contrast to the other groups. No MMN or P3a differences were found between patients with bipolar disorder taking (n = 12) and not taking (n = 40) lithium, as well as between those taking (n = 30) and not taking (n = 22) antipsychotic medications. CONCLUSIONS: Patients with bipolar disorder showed deficits in preattentive auditory processing, including MMN deficits that are less severe and P3a deficits that are slightly more pronounced, than those seen in schizophrenia.
Asunto(s)
Trastorno Bipolar/diagnóstico , Trastorno Bipolar/fisiopatología , Variación Contingente Negativa/fisiología , Potenciales Relacionados con Evento P300/fisiología , Esquizofrenia/diagnóstico , Esquizofrenia/fisiopatología , Estimulación Acústica , Adulto , Análisis de Varianza , Trastorno Bipolar/clasificación , Trastorno Bipolar/tratamiento farmacológico , Mapeo Encefálico , Variación Contingente Negativa/efectos de los fármacos , Electroencefalografía , Potenciales Relacionados con Evento P300/efectos de los fármacos , Femenino , Lateralidad Funcional , Humanos , Cloruro de Litio/farmacología , Cloruro de Litio/uso terapéutico , Masculino , Persona de Mediana Edad , Escalas de Valoración PsiquiátricaRESUMEN
Elevated smoking rates have been noted in schizophrenia, and it has been hypothetically attributed to nicotine's ameliorating abnormal brain processes in this illness. There is some preliminary evidence that nicotine may alter pre-attentive auditory change detection, as indexed by the EEG-derived mismatch negativity (MMN), but no previous study has examined what role auditory verbal hallucinations (AVH) may have on these effects. The objective of this study was to examine MMN-indexed acoustic change detection in schizophrenia (SZ) following nicotine administration and elucidate its association with AVH. Using a modified multi-feature paradigm, MMNs to duration, frequency and intensity deviants were recorded in 12 schizophrenia outpatients (SZ) with persistent AVHs following nicotine (6mg) and placebo administration. Electrical activity was recorded from 32 scalp electrodes; MMN amplitudes and latencies for each deviant were compared between treatments and were correlated with trait (PSYRATS) and state measures of AVH severity and Positive and Negative Syndrome Scale (PANSS) ratings. Nicotine administration resulted in a shortened latency for intensity MMN. Additionally, nicotine-related change in MMN amplitude was correlated with nicotine-related change in subjective measures of hallucinatory state. In summary, nicotine did not affect MMN amplitudes in schizophrenia patients with persistent AVHs, however this study reports accelerated auditory change detection to intensity deviants with nicotine in this group. Additionally, nicotine appeared to induce a generalized activation of the auditory cortex in schizophrenia, resulting in a concurrent increase in intensity MMN amplitude and subjective clarity of AVHs.
Asunto(s)
Encéfalo/fisiopatología , Variación Contingente Negativa/efectos de los fármacos , Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Esquizofrenia/complicaciones , Estimulación Acústica , Adulto , Presión Sanguínea/efectos de los fármacos , Encéfalo/efectos de los fármacos , Estudios Transversales , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Electroencefalografía , Femenino , Alucinaciones/etiología , Alucinaciones/patología , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración PsiquiátricaRESUMEN
The significance of the mismatch negativity (MMN), an event-related potential measured in humans which indexes novelty in the auditory environment, has motivated a search for a cellular correlate of this process. A leading candidate is stimulus-specific adaptation (SSA) in auditory cortex units, which shares several characteristics with the MMN. Whether auditory cortex responses encode sensory novelty, a defining property of the MMN, however, has not been resolved. To evaluate this key issue, we used several variations of the auditory oddball paradigm from the human literature and examined psychophysical and pharmacological properties of multiunit activity in the auditory cortex of awake rodents. We found converging evidence dissociating SSA from sensory novelty and the MMN. First, during an oddball paradigm with frequency deviants, neuronal responses showed clear SSA but failed to encode novelty in a manner analogous to the human MMN. Second, oddball paradigms using intensity or duration deviants revealed a pattern of unit responses that showed sensory adaptation, but again without any measurable novelty correlates aligning to the human MMN. Finally NMDA antagonists, which are known to disrupt the MMN, suppressed the magnitude of multiunit responses in a nonspecific manner, leaving the process of SSA intact. Together, our results suggest that auditory novelty detection as indexed by the MMN is dissociable from SSA at the level of activity encoded by auditory cortex neurons. Further, the NMDA sensitivity reported for the MMN, which models the disruption of MMN observed in schizophrenia, may occur at a mechanistic locus outside of SSA.
Asunto(s)
Adaptación Fisiológica/fisiología , Corteza Auditiva/fisiología , Percepción Auditiva/fisiología , Variación Contingente Negativa/fisiología , Potenciales Evocados Auditivos/fisiología , N-Metilaspartato/metabolismo , Estimulación Acústica/métodos , Adaptación Fisiológica/efectos de los fármacos , Análisis de Varianza , Animales , Corteza Auditiva/efectos de los fármacos , Percepción Auditiva/efectos de los fármacos , Variación Contingente Negativa/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Electroencefalografía/métodos , Potenciales Evocados Auditivos/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Psicoacústica , Ratas , Roedores , Vigilia/fisiologíaRESUMEN
Mismatch negativity (MMN) is an auditory event-related potential indicating auditory sensory memory and information processing. The present study tested the hypothesis that chronic cannabis use is associated with deficient MMN generation. MMN was investigated in age- and gender-matched chronic cannabis users (n = 30) and nonuser controls (n = 30). The cannabis users were divided into two groups according to duration and quantity of cannabis consumption. The MMNs resulting from a pseudorandomized sequence of 2 × 900 auditory stimuli were recorded by 32-channel EEG. The standard stimuli were 1,000 Hz, 80 dB SPL and 90 ms duration. The deviant stimuli differed in duration (50 ms) or frequency (1,200 Hz). There were no significant differences in MMN values between cannabis users and nonuser controls in both deviance conditions. With regard to subgroups, reduced amplitudes of frequency MMN at frontal electrodes were found in long-term (≥8 years of use) and heavy (≥15 joints/week) users compared to short-term and light users. The results indicate that chronic cannabis use may cause a specific impairment of auditory information processing. In particular, duration and quantity of cannabis use could be identified as important factors of deficient MMN generation.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Electroencefalografía , Potenciales Evocados Auditivos/efectos de los fármacos , Abuso de Marihuana , Estimulación Acústica , Adulto , Corteza Auditiva/efectos de los fármacos , Corteza Auditiva/fisiopatología , Percepción Auditiva/efectos de los fármacos , Trastornos del Conocimiento/etiología , Trastornos del Conocimiento/fisiopatología , Dronabinol/farmacología , Femenino , Alucinógenos/farmacología , Humanos , Masculino , Abuso de Marihuana/complicaciones , Abuso de Marihuana/metabolismo , Abuso de Marihuana/fisiopatología , Trastornos de la Memoria/etiología , Trastornos de la Memoria/fisiopatología , Receptores de Cannabinoides/metabolismo , TiempoRESUMEN
Antagonists of the N-methyl-D-aspartate (NMDA) receptors such as ketamine, induce abnormalities in healthy subjects similar to those found in schizophrenia. However, recent evidence, suggests that most of the currently known NMDA antagonists have a broader receptor profile than originally thought. Besides exerting an antagonistic effect on NMDA receptors, they have agonistic effects on dopamine D2 receptors. Can haloperidol (D2 antagonist) counteract the disruptive effects of ketamine on psychophysiological parameters of human attention? In a randomized, double-blind, placebo-controlled experiment 18 healthy male volunteers received placebo/placebo, placebo/ketamine (0.3 mg/kg i.v.) and haloperidol (2 mg)/ketamine (0.3 mg/kg i.v.) on three separate test days, after which they were tested in an auditory selective-attention paradigm. Haloperidol/ketamine reduced task performance compared to placebo/placebo, while the task performance in these two treatments did not differ from placebo/ketamine. Furthermore, placebo/ketamine reduced processing negativity compared to both placebo/placebo and haloperidol/ketamine, while processing negativity did not differ between placebo/placebo and haloperidol/ketamine treatments. However, both placebo/ketamine and haloperidol/ketamine reduced P300 amplitude compared to placebo/placebo, while P300 amplitude did not differ between placebo/ketamine and haloperidol/ketamine treatments. The combined effects of haloperidol and ketamine reduced task performance, suggesting that this is dependent on dopaminergic D2 activity, probably in the prefrontal cortex. In addition, ketamine reduced both P300 amplitude and processing negativity. In contrast to the P300 amplitude, the disruptive effects of ketamine on processing negativity could be prevented by pretreatment with haloperidol. The current results suggest that ketamine reduced P300 amplitude by its antagonistic effect on glutamatergic activity, while it reduced processing negativity by its agonistic effect on dopaminergic D2 activity.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Antagonistas de Dopamina/farmacología , Potenciales Relacionados con Evento P300/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Haloperidol/farmacología , Ketamina/farmacología , Estimulación Acústica/métodos , Adulto , Afecto/efectos de los fármacos , Atención/efectos de los fármacos , Conducta/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Interacciones Farmacológicas , Electroencefalografía/métodos , Electrooculografía/métodos , Frecuencia Cardíaca/efectos de los fármacos , Ácido Homovanílico/sangre , Humanos , Ketamina/sangre , Masculino , Análisis Multivariante , Pruebas Neuropsicológicas , Prolactina/sangre , Escalas de Valoración Psiquiátrica , Tiempo de Reacción/efectos de los fármacos , Factores de Tiempo , Adulto JovenRESUMEN
Thirteen of 20 normal adults given 10 milligrams of dextroamphetamine exhibited paradoxical drowsiness accompanied by lowered electrical brain activity (contingent negative variation, or CNV) in the first hour post-drug. During this period, seven subjects showed behavioral alertness and increased CNV amplitude. Both groups of subjects showed heightened alertness 2 and 3 hours post-drug. Amphetamine is not a simple stimulant of the central nervous system but can also act as a depressant.
Asunto(s)
Atención/efectos de los fármacos , Dextroanfetamina/farmacología , Electroencefalografía , Vigilia/efectos de los fármacos , Estimulación Acústica , Adolescente , Adulto , Encéfalo/efectos de los fármacos , Variación Contingente Negativa/efectos de los fármacos , Depresión Química , Femenino , Humanos , Estimulación Luminosa , Tiempo de Reacción/efectos de los fármacos , Factores de TiempoRESUMEN
INTRODUCTION: Cholinergic agonists and, more specifically, nicotine, have been found to enhance a number of cognitive processes. The effect of nicotine on temporal processing is not known. The use of behavioral measures of temporal processing to measure its effect could be confounded by the general effects of nicotine on attention. Mismatch negativity (MMN) has been used as a physiological measure of automatic temporal processing to avoid this potential confound. METHODS: A total of 20 subjects (11 nonsmokers and 9 smokers following 2 hr of abstinence) participated in a two-visit single-blind, placebo-controlled crossover study of the effect of nicotine on MMN indices in response to an interstimulus interval deviant. RESULTS: Nicotine-enhanced MMN amplitudes from baseline recording to postdrug recording greater than did the placebo condition. This enhancement was seen in both nonsmokers and smokers. Nicotine had no significant effect on MMN latency or N100 amplitude or latency. DISCUSSION: This is the first study to demonstrate a nicotine-related enhancement of MMN amplitude to an interstimulus interval duration deviant and confirms our hypothesis that nicotine enhances preattentive temporal processing. Nicotinic agonists may represent a potential therapeutic option for individuals with abnormalities in early sensory or temporal processing related to cholinergic system abnormalities. Methodologically, our paradigm of nicotine administration in abstinent smokers is important because it resulted in both minimal withdrawal symptoms and meaningful data that are not attributable solely to relief of withdrawal.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Potenciales Evocados Auditivos/efectos de los fármacos , Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Estimulación Acústica/métodos , Adulto , Percepción Auditiva/efectos de los fármacos , Percepción Auditiva/fisiología , Variación Contingente Negativa/fisiología , Estudios Cruzados , Electroencefalografía/métodos , Potenciales Evocados Auditivos/fisiología , Femenino , Humanos , Masculino , Tiempo de Reacción/efectos de los fármacos , Método Simple Ciego , Adulto JovenRESUMEN
Attention deficit hyperactivity disorder (ADHD) has been linked to abnormal functioning of cortical motor areas such as the supplementary motor area, the premotor cortex and primary motor cortex (MI). The Bereitschaftspotential (BP) and lateralized readiness potential (LRP) are movement-related potentials generated by cortical motor areas. We hypothesized that the BP and LRP would be altered in children with ADHD. A group of 17 children with ADHD (mean age: 11.5⯱â¯1.9 years) and a control group of 16 typically developing children (mean age: 12.2 ±â¯2.0 years) performed movements at self-chosen irregular intervals while a 64-channel DC-EEG was registered. BP and LRP were calculated from the EEG. The ADHD group had significantly lower and on average positive BP amplitudes at Cz. In agreement with age-dependent maturation effects the LRP had a positive polarity in both groups, but lower amplitudes were found in the ADHD group without medication. The control group showed a mid-central negativity and a positivity over motor areas contra-lateral to the side of movement, whereas no negativity over Cz and a more diffuse positivity was found in the ADHD group. LRP group differences diminished after MPH administration as indicated by an interaction between group and time of measurement/medication. The cortical motor system shows altered functioning during movement preparation and initiation in children affected by ADHD. Positive Bereitschaftspotential polarities may represent delayed cortical maturation. Group differences of LRP were pharmacologically modulated by the catecholaminergic agent MPH.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/fisiopatología , Encéfalo/fisiopatología , Variación Contingente Negativa , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/uso terapéutico , Niño , Variación Contingente Negativa/efectos de los fármacos , Estudios Transversales , Electroencefalografía , Electromiografía , Femenino , Humanos , Masculino , Metilfenidato/uso terapéutico , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiologíaRESUMEN
In schizophrenia patients, glutathione dysregulation at the gene, protein and functional levels, leads to N-methyl-D-aspartate (NMDA) receptor hypofunction. These patients also exhibit deficits in auditory sensory processing that manifests as impaired mismatch negativity (MMN), which is an auditory evoked potential (AEP) component related to NMDA receptor function. N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients to determine whether increased levels of brain glutathione would improve MMN and by extension NMDA function. A randomized, double-blind, cross-over protocol was conducted, entailing the administration of NAC (2 g/day) for 60 days and then placebo for another 60 days (or vice versa). 128-channel AEPs were recorded during a frequency oddball discrimination task at protocol onset, at the point of cross-over, and at the end of the study. At the onset of the protocol, the MMN of patients was significantly impaired compared to sex- and age- matched healthy controls (p=0.003), without any evidence of concomitant P300 component deficits. Treatment with NAC significantly improved MMN generation compared with placebo (p=0.025) without any measurable effects on the P300 component. MMN improvement was observed in the absence of robust changes in assessments of clinical severity, though the latter was observed in a larger and more prolonged clinical study. This pattern suggests that MMN enhancement may precede changes to indices of clinical severity, highlighting the possible utility AEPs as a biomarker of treatment efficacy. The improvement of this functional marker may indicate an important pathway towards new therapeutic strategies that target glutathione dysregulation in schizophrenia.
Asunto(s)
Acetilcisteína/farmacología , Variación Contingente Negativa/efectos de los fármacos , Potenciales Evocados Auditivos/efectos de los fármacos , Depuradores de Radicales Libres/farmacología , Esquizofrenia/fisiopatología , Acetilcisteína/uso terapéutico , Estimulación Acústica/métodos , Adulto , Mapeo Encefálico , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/fisiopatología , Estudios Cruzados , Discriminación en Psicología/efectos de los fármacos , Método Doble Ciego , Electroencefalografía , Femenino , Depuradores de Radicales Libres/uso terapéutico , Glutatión/sangre , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Tiempo de Reacción/efectos de los fármacos , Estudios Retrospectivos , Esquizofrenia/sangre , Esquizofrenia/tratamiento farmacológico , Esquizofrenia/patología , Factores de TiempoRESUMEN
INTRODUCTION: The psychomotor stimulant methylphenidate (MPH) has been shown to improve attentional processes, reflected in behavioural measures such as vigilance, reaction time and visual attention tasks. The neural mechanisms of MPH action on sensory information processing, however, remain poorly understood. To the authors' knowledge, this present study is the first to investigate whether a single dose of MPH affects neural substrates of passive attention in healthy adults studied with simultaneous whole-head magnetoencephalography (MEG) and electroencephalography (EEG). METHODS: Monaural left-ear auditory stimuli were presented in an oddball paradigm with infrequent deviant tones differing in frequency and duration. Neuronal activity was recorded with simultaneous whole-head MEG and EEG in 13 healthy subjects (five females; aged 27 +/- 5 years) after oral administration of 40 mg MPH or placebo in a randomised, double-blind, cross-over design. We analysed both electric and magnetic N100, P200 and mismatch negativity (MMN) components. RESULTS: MPH increased arousal levels in visual analogue scales. MPH had no effect on the dipole strength of MMN or MMNm in either frequency or duration deviations. MPH did, however, reduce P200 amplitudes in EEG. CONCLUSIONS: The lack of effect of MPH on either MMN or MMNm suggests no association between catecholaminergic activities and MMN generation. However, our findings imply that MPH may change the neural bases of auditory information processing such as the early stimulus evaluation reflected in the P200 component. Dopamine and noradrenaline neurotransmitter systems could be responsible for the modulation of these processes. The exclusive effect of MPH on the P200 component could have a clinical application.
Asunto(s)
Atención/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/farmacología , Electroencefalografía/efectos de los fármacos , Magnetoencefalografía/efectos de los fármacos , Metilfenidato/farmacología , Discriminación de la Altura Tonal/efectos de los fármacos , Percepción del Tiempo/efectos de los fármacos , Estimulación Acústica , Adulto , Nivel de Alerta/efectos de los fármacos , Mapeo Encefálico , Corteza Cerebral/efectos de los fármacos , Variación Contingente Negativa/efectos de los fármacos , Dominancia Cerebral/fisiología , Potenciales Evocados Auditivos/efectos de los fármacos , Femenino , Humanos , Masculino , Tiempo de Reacción/efectos de los fármacosRESUMEN
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states. Previous studies reported a significant reduction of MMN after ketamine (N-methyl-D-aspartate acid [NMDA] antagonist model) but not after psilocybin (5HT2A agonist model). OBJECTIVES: The aim of the present study was to directly compare the two models of psychosis using an intraindividual crossover design. MATERIALS AND METHODS: Fifteen healthy subjects participated in a randomized, double-blind, crossover study with a low and a high dose of the 5HT2A agonist dimethyltryptamine (DMT) and the NMDA antagonist S-ketamine. During electroencephalographic recording, the subjects were performing the AX-version of a continuous performance test (AX-CPT). A source analysis of MMN was performed on the basis of a four-source model of MMN generation. RESULTS: Nine subjects completed both experimental days with the two doses of both drugs. Overall, we found blunted MMN and performance deficits in the AX-CPT after both drugs. However, the reduction in MMN activity was overall more pronounced after S-ketamine intake, and only S-ketamine had a significant impact on the frontal source of MMN. CONCLUSIONS: The NDMA antagonist model and the 5HT2A agonist model of psychosis display distinct neurocognitive profiles. These findings are in line with the view of the two classes of hallucinogens modeling different aspects of psychosis.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Ketamina/farmacología , N,N-Dimetiltriptamina/farmacología , Psicosis Inducidas por Sustancias/fisiopatología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Agonistas del Receptor de Serotonina 5-HT2 , Agonistas de Receptores de Serotonina/farmacología , Adulto , Atención/efectos de los fármacos , Percepción Auditiva/efectos de los fármacos , Mapeo Encefálico , Corteza Cerebral/efectos de los fármacos , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Electroencefalografía/efectos de los fármacos , Femenino , Humanos , Inhibición Psicológica , Masculino , Persona de Mediana Edad , Orientación/efectos de los fármacos , Reconocimiento Visual de Modelos/efectos de los fármacos , Desempeño Psicomotor/efectos de los fármacos , Reflejo de Sobresalto/efectos de los fármacos , Procesamiento de Señales Asistido por ComputadorRESUMEN
The effect of the antimigraine drug rizatriptan on the amplitude and habituation of the contingent negative variation (CNV) in healthy women was examined in a randomized, double-blind, placebo-controlled trial. The test persons were assigned either to a drug (n = 20) or a placebo group (n = 20). The CNV was recorded three times: before, directly after, and 24 h after drug or placebo intake. The CNV paradigm was presented in a standard, a cued and a choice version. Rizatriptan led to an increase of CNV amplitude that depended on the level of difficulty of the task. Whereas there was no drug effect in the standard version, an amplitude increase was obtained mainly in the choice task. The results are in line with the ceiling theory of migraine, which assumes a rise of CNV amplitude if the serotonin level is lowered.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Agonistas de Receptores de Serotonina/farmacología , Triazoles/farmacología , Triptaminas/farmacología , Adulto , Nivel de Alerta/fisiología , Método Doble Ciego , Electroencefalografía/efectos de los fármacos , Femenino , Habituación Psicofisiológica , Humanos , Modelos Neurológicos , Valores de Referencia , Serotonina/fisiologíaRESUMEN
In the human brain, auditory sensory memory has been extensively studied using a well-defined component of event-related potential named the mismatch negativity (MMN). The MMN is generated in the auditory and frontal cortices in response to deviant stimuli. In monkeys, cortical N-methyl-d-aspartate (NMDA) receptors have a central role in the generation of the MMN. MMN-like responses have also been recorded in other animals, including rats. The present study aimed at determining whether the MMN-like response in rats depends on an intact NMDA-receptor system. We recorded auditory evoked responses during an oddball paradigm epidurally in anesthetized rats that had received intraperitoneal injections of saline or an NMDA-receptor antagonist MK-801. An MMN-like response was recorded in the oddball paradigm in saline-treated rats. Further, this response was dose-dependently blocked by MK-801. These results suggest that the MMN-like response in rats depends on an intact NMDA-receptor system.
Asunto(s)
Corteza Auditiva/efectos de los fármacos , Variación Contingente Negativa/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Agonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/farmacología , N-Metilaspartato/farmacología , Estimulación Acústica/métodos , Análisis de Varianza , Anestesia , Animales , Corteza Auditiva/fisiología , Relación Dosis-Respuesta a Droga , Electroencefalografía , Masculino , Ratas , Tiempo de Reacción/efectos de los fármacosRESUMEN
Migraine is characterized by reduced habituation of multimodal evoked potentials, which in turn reflects an abnormal pattern of cortical excitability. We assessed the effects of a 2-month treatment with topiramate or levetiracetam vs placebo on contingent negative variation (CNV) habituation and amplitude in a cohort of migraine without aura (MO) patients. Forty-five MO patients were selected from a university-based outpatient clinic and randomly assigned to 100mg topiramate or 1000mg levetiracetam or placebo in a double-blind design. Twenty-four control subjects were also recruited. The initial CNV (iCNV) amplitude and habituation were assessed by Cz/A1-A2 derivation recordings in the basal condition (T0) and after 2 months of treatment (T1). Both topiramate and levetiracetam produced a significant reduction in migraine frequency compared to placebo, they also reversed the abnormal iCNV habituation pattern which characterized the MO patients in the basal condition and which was not present in controls. For migraine patients, the reduced migraine frequency and habituation index following treatment were significantly correlated. A lack of habituation of evoked responses is an interictal endophenotypic marker in migraine, the reversion of which may improve disease outcome. These results suggest a role for neurophysiological methods in the management of migraine.
Asunto(s)
Anticonvulsivantes/farmacología , Variación Contingente Negativa/efectos de los fármacos , Habituación Psicofisiológica/efectos de los fármacos , Migraña sin Aura/fisiopatología , Piracetam/análogos & derivados , Estimulación Acústica/métodos , Adolescente , Adulto , Análisis de Varianza , Anticonvulsivantes/uso terapéutico , Método Doble Ciego , Electroencefalografía , Femenino , Fructosa/análogos & derivados , Fructosa/uso terapéutico , Humanos , Levetiracetam , Masculino , Persona de Mediana Edad , Migraña sin Aura/tratamiento farmacológico , Piracetam/farmacología , Piracetam/uso terapéutico , Factores de Tiempo , TopiramatoRESUMEN
Major depressive disorder (MDD) is characterized by disturbances of mood and affect, but also by a distinct pattern of psychomotor and cognitive deficits such as motor retardation and impaired executive functioning. An important aspect of executive functioning is performance monitoring, i.e., a continuous checking whether intended action goals have been reached and whether correction of the applied strategy is necessary. A well-known marker for action monitoring is the error negativity (Ne) or error-related negativity (ERN), an event-related potential (ERP) component generated in the anterior cingulate cortex (ACC) following erroneous responses. To date, Ne/ERN amplitudes have been investigated in moderately depressed patients only. The present study is the first to investigate action monitoring in severely depressed patients (mean Hamilton score=28.4). In addition, the patients' psychomotor performance was assessed to see whether there is a relationship between action monitoring and psychomotor retardation. Behavioural and ERP measurements were obtained during performance on a speeded two-choice reaction task in 26 patients with MDD and 25 healthy, matched controls. Psychomotor performance measures were speed of simple movements in various psychomotor tasks and the score on the Salpêtrière retardation rating scale (SRRS). Relative to the controls, the patients' behavioural results revealed a similar, but slower performance pattern. Overall between-group differences were demonstrated for the error positivity (Pe) amplitudes, but not for the Ne/ERN amplitudes. However, correlations of the Ne/ERN amplitude with several psychomotor variables were strong. In the depressed patients taking benzodiazepines an additional attenuation of Ne/ERN amplitudes was observed. Only severely depressed patients manifesting retardation showed impeded action monitoring. The correlations between action monitoring and psychomotor performance indicate that in MDD these two processes are highly interdependent, both being deregulated. Moreover, the same network of brain regions is likely to be implicated in both processes.
Asunto(s)
Variación Contingente Negativa/fisiología , Trastorno Depresivo Mayor/fisiopatología , Intención , Trastornos Psicomotores/fisiopatología , Tiempo de Reacción/fisiología , Adulto , Antidepresivos/uso terapéutico , Benzodiazepinas/uso terapéutico , Estudios de Casos y Controles , Conducta de Elección/efectos de los fármacos , Conducta de Elección/fisiología , Variación Contingente Negativa/efectos de los fármacos , Trastorno Depresivo Mayor/complicaciones , Trastorno Depresivo Mayor/tratamiento farmacológico , Femenino , Giro del Cíngulo/fisiología , Humanos , Masculino , Análisis por Apareamiento , Persona de Mediana Edad , Trastornos Psicomotores/complicaciones , Desempeño Psicomotor/efectos de los fármacos , Desempeño Psicomotor/fisiología , Tiempo de Reacción/efectos de los fármacos , Valores de Referencia , Autoimagen , Índice de Severidad de la EnfermedadRESUMEN
One of the most robust electrophysiological features of schizophrenia is reduced mismatch negativity, a component of the event related potential (ERP) induced by rare and unexpected stimuli in an otherwise regular pattern. Emerging evidence suggests that mismatch negativity (MMN) is not the only ERP index of deviance detection in the mammalian brain and that sensitivity to deviant sounds in a regular background can be observed at earlier latencies in both the human and rodent brain. Pharmacological studies in humans and rodents have previously found that MMN reductions similar to those seen in schizophrenia can be elicited by N-methyl-d-aspartate (NMDA) receptor antagonism, an observation in agreement with the hypothesised role of NMDA receptor hypofunction in schizophrenia pathogenesis. However, it is not known how NMDA receptor antagonism affects early deviance detection responses. Here, we show that NMDA antagonism impacts both early and late deviance detection responses. By recording EEG in awake, freely-moving rats in a drug-free condition and after varying doses of NMDA receptor antagonist MK-801, we found the hypothesised reduction of deviance detection for a late, negative potential (N55). However, the amplitude of an early component, P13, as well as deviance detection evident in the same component, were increased by NMDA receptor antagonism. These findings indicate that late deviance detection in rats is similar to human MMN, but the surprising effect of MK-801 in increasing ERP amplitudes as well as deviance detection at earlier latencies suggests that future studies in humans should examine ERPs over early latencies in schizophrenia and after NMDA antagonism.
Asunto(s)
Variación Contingente Negativa/efectos de los fármacos , Maleato de Dizocilpina/farmacología , Potenciales Evocados Auditivos/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Estimulación Acústica , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Electroencefalografía , Masculino , Ratas , Ratas WistarRESUMEN
BACKGROUND: Deficits in N-methyl-d-aspartate-type (NMDAR) function contribute to symptoms and cognitive dysfunction in schizophrenia. The efficacy of NMDAR agonists in the treatment of persistent symptoms of schizophrenia has been variable, potentially reflecting limitations in functional target engagement. We recently demonstrated significant improvement in auditory mismatch negativity (MMN) with once-weekly treatment with d-serine, a naturally occurring NMDAR glycine-site agonist. This study investigates effects of continuous (daily) NMDAR agonists in schizophrenia/schizoaffective disorder. METHODS: Primary analysis was on MMN after double-blind crossover (60mg/kg/d, n=16, 6weeks) treatment with d-serine/placebo. Secondary measures included clinical symptoms, neurocognition, and the effects of open-label (30-120mg/kg/d, n=21) d-serine and bitopertin/placebo (10mg, n=29), a glycine transport inhibitor. RESULTS: Double-blind d-serine treatment led to significant improvement in MMN frequency (p=0.001, d=2.3) generation and clinical symptoms (p=0.023, d=0.80). MMN frequency correlated significantly with change in symptoms (r=-0.63, p=0.002) following co-variation for treatment type. d-Serine treatment led to a significant, large effect size increase vs. placebo in evoked α-power in response to standards (p=0.036, d=0.81), appearing to normalize evoked α power relative to previous findings with controls. While similar results were seen with open-label d-serine, no significant effects of bitopertin were observed for symptoms or MMN. CONCLUSIONS: These findings represent the first randomized double-blind placebo-controlled study with 60mg/kg d-serine in schizophrenia, and are consistent with meta-analyses showing significant effects of d-serine in schizophrenia. Results overall support suggest that MMN may have negative, as well as positive, predictive value in predicting efficacy of novel compounds. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov: NCT00322023/NCT00817336 (d-serine); NCT01116830 (bitopertin).
Asunto(s)
Antipsicóticos/uso terapéutico , Variación Contingente Negativa/efectos de los fármacos , Potenciales Evocados Auditivos/fisiología , Esquizofrenia/tratamiento farmacológico , Serina/uso terapéutico , Estimulación Acústica , Adolescente , Adulto , Trastornos del Conocimiento/etiología , Estudios Cruzados , Método Doble Ciego , Potenciales Evocados Auditivos/efectos de los fármacos , Femenino , Humanos , Masculino , Metaanálisis como Asunto , Persona de Mediana Edad , Piperazinas/uso terapéutico , Esquizofrenia/fisiopatología , Sulfonas/uso terapéutico , Factores de Tiempo , Adulto JovenRESUMEN
N-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction has been implicated in the pathophysiology of schizophrenia, including auditory processing abnormalities reflected by the mismatch negativity (MMN) event-related potential component. Evidence suggesting cognitive benefits from nicotine administration, together with the high rate of cigarette use in patients with schizophrenia, has stimulated interest in whether nicotine modulates NMDAR hypofunction. We examined the interactive effects of ketamine, an NMDAR antagonist that produces transient schizophrenia-like neurophysiological effects, and nicotine, a nicotinic acetylcholine receptor (nAChR) agonist, in 30 healthy volunteers to determine whether nicotine prevents or attenuates MMN abnormalities. Secondary analyses compared the profile of ketamine and schizophrenia effects on MMN using previously reported data from 24 schizophrenia patients (Hay et al. 2015). Healthy volunteers completed four test days, during which they received ketamine/placebo and nicotine/placebo in a double-blind, counterbalanced design. MMN to intensity, frequency, duration, and frequency+duration double deviant sounds was assessed each day. Ketamine decreased intensity, frequency, and double deviant MMN amplitudes, whereas nicotine increased intensity and double deviant MMN amplitudes. A ketamine×nicotine interaction indicated, however, that nicotine failed to attenuate the decrease in MMN associated with ketamine. Although the present dose of ketamine produced smaller decrements in MMN than those associated with schizophrenia, the profile of effects across deviant types did not differ between ketamine and schizophrenia. Results suggest that while ketamine and schizophrenia produce similar profiles of MMN effects across deviant types, nicotinic agonists may have limited potential to improve these putative NMDAR hypofunction-mediated impairments in schizophrenia.